What is the primary function of the anti-HIgG(Fc)Fab-N-DM1 ADC?

The primary function of this ADC (Antibody-Drug Conjugate) is to serve as a pre-screening tool for human monoclonal antibodies as ADC candidates. It binds to tubulins, disrupts microtubule dynamics, and induces cell death when paired with a primary antibody.

What is the primary research application of anti-HIgG(Fc)Fab-N-DM1 ADC?

The primary application of this ADC product is to serve as a tool in pre-screening human monoclonal antibodies for potential use as ADC candidates.

How does the anti-HIgG(Fc)Fab-N-DM1 ADC mechanism of action work?

This ADC combines a Fab fragment of an anti-human IgG Fc specific polyclonal antibody with DM1 via a noncleavable linker. DM1, a cytotoxic molecule, binds to tubulins, disrupting microtubule dynamics and inducing cell death.

Can the anti-HIgG(Fc)Fab-N-DM1 ADC be used in therapeutic applications directly?

This product is primarily designed for research use, specifically for the pre-screening of human monoclonal antibodies and is not intended for direct therapeutic use.

What types of cells can be targeted with the anti-HIgG(Fc)Fab-N-DM1 ADC?

The target cells are those that would bind the anti-human IgG Fc segment of the ADC, typically cells engineered to express human IgG Fc or cells coated with human IgG Fc antibodies.

What assays are recommended to measure the efficacy of the anti-HIgG(Fc)Fab-N-DM1 ADC?

Efficacy can be assessed through cell viability assays, flow cytometry, and western blot analysis to evaluate the ADC's ability to bind, internalize, and induce cytotoxicity in target cells.

Home
Products
Anti-Ab ADCs
IgG Fc
anti-HIgG(Fc)Fab-N-DM1 ADC

anti-HIgG(Fc)Fab-N-DM1 ADC (CAT#: ADC-AA-015)

This ADC product is comprised of a Fab fragment of an anti-human IgG Fc specific polyclonal antibody conjugated via a noncleavable linker to DM1. The antibody portion is a Fab fragment of a secondary antibody and the drug portion, DM1, is a cytotoxic small molecule which binds to tubulins, interrupts microtubule dynamics, and induces cell death. This product displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening human monoclonal antibodies as ADC candidates.

ADC Target
ADC Antibody
ADC Linker
ADC payload drug

Name
IgG Fc

Overview
The fragment crystallizable region (Fc region) is composed of the constant region of the two heavy chains that form the IgG molecule. The Fc region of IgG bears a highly conserved N-glycosylation site. Glycosylation of the Fc fragment is essential for Fc receptor-mediated activity. Fc binds to various cell receptors and complement proteins thus mediating different physiological effects of antibodies, such as opsonization, antibody dependent cellular cytotoxicity (ADCC), degranulation of mast cells, basophils, eosinophils and other processes.

Overview
Fab fragment of anti-human IgG Fc specific polyclonal antibody

Species Reactivity
Human

Name
Noncleavable linkers

Description
Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.

Name
DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

Description
Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa
macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-AA-015. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

Creative Biolabs' anti-HIgG(Fc)Fab-N-DM1 ADC has dramatically improved our screening process. The noncleavable linker and DM1's tubulin-binding efficacy make it a reliable tool for targeting cell structures without unwanted toxicity.

Excellent

Using the anti-HIgG(Fc)Fab-N-DM1 ADC, we've seen precise targeting and effective induction of cell death in our studies. Its stability and consistent performance are impressive.

Excellent

The noncleavable linker in this ADC ensures that DM1 remains bound and effective, which is crucial for our studies involving microtubule dynamics. It's been an essential part of our research toolkit.

Excellent

I highly recommend the anti-HIgG(Fc)Fab-N-DM1 ADC for its efficacy and safety. It provides a cost-effective method for pre-screening ADC candidates, significantly cutting down our lab's expenses.

Excellent

This ADC product from Creative Biolabs has been a game changer in our ADC development, providing targeted cytotoxicity with minimal off-target effects. It's particularly useful for labs focused on enhancing precision in drug delivery.

Excellent

The anti-HIgG(Fc)Fab-N-DM1 ADC is a standout in our lab for its robust performance in inducing targeted cell death without systemic toxicity. It has streamlined our workflow and improved our screening outcomes.

Q: 1: What is the primary function of the anti-HIgG(Fc)Fab-N-DM1 ADC?
A: The primary function of this ADC (Antibody-Drug Conjugate) is to serve as a pre-screening tool for human monoclonal antibodies as ADC candidates. It binds to tubulins, disrupts microtubule dynamics, and induces cell death when paired with a primary antibody.
Q: 2: What is the primary research application of anti-HIgG(Fc)Fab-N-DM1 ADC?
A: The primary application of this ADC product is to serve as a tool in pre-screening human monoclonal antibodies for potential use as ADC candidates.
Q: 3: How does the anti-HIgG(Fc)Fab-N-DM1 ADC mechanism of action work?
A: This ADC combines a Fab fragment of an anti-human IgG Fc specific polyclonal antibody with DM1 via a noncleavable linker. DM1, a cytotoxic molecule, binds to tubulins, disrupting microtubule dynamics and inducing cell death.
Q: 4: Can the anti-HIgG(Fc)Fab-N-DM1 ADC be used in therapeutic applications directly?
A: This product is primarily designed for research use, specifically for the pre-screening of human monoclonal antibodies and is not intended for direct therapeutic use.
Q: 5: What types of cells can be targeted with the anti-HIgG(Fc)Fab-N-DM1 ADC?
A: The target cells are those that would bind the anti-human IgG Fc segment of the ADC, typically cells engineered to express human IgG Fc or cells coated with human IgG Fc antibodies.
Q: 6: What assays are recommended to measure the efficacy of the anti-HIgG(Fc)Fab-N-DM1 ADC?
A: Efficacy can be assessed through cell viability assays, flow cytometry, and western blot analysis to evaluate the ADC's ability to bind, internalize, and induce cytotoxicity in target cells.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload

CAT#	Product Name	Linker	Payload
ADC-AA-029	anti-MIgG(Fc)Fab-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)
ADC-AA-031	anti-MIgG(Fc)Fab-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-027	anti-MIgG(Fc)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-048	Protein G-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)
ADC-AA-028	anti-MIgG(Fc)Fab-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)

CAT#	Product Name	Linker	Payload
ADC-AA-063	Anti-HIgG(Fab)-N-MMAF ADC	Noncleavable linkers	MMAF
ADC-AA-037	anti-RIgG(HL)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-046	anti-Rat IgG(HL)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-027	anti-MIgG(Fc)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-039	anti-Rat IgG(Fc)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)

CAT#	Product Name	Linker	Payload
ADC-W-572	Anti-ERBB2 (Trastuzumab-Fab)-SPP-DM1 ADC	SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-495	Anti-EGFR (J2898A)-SMCC-DM1 ADC	SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-054	Protein A-MCC-DM1 ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-541	Anti-CD44 (clone BIWA 4)-DM1 ADC		DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-487	Anti-CD70-MCC-DM1 ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.